Back to top
more

CASI Pharmaceuticals Inc. (CASI)

(Delayed Data from NSDQ)

$1.47 USD

1.47
296,851

-0.21 (-12.50%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.45 -0.02 (-1.36%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 44.44% and 16.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.

Zacks Equity Research

Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

by Zacks Equity Research

Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

Zacks Equity Research

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Zacks Equity Research

Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down

by Zacks Equity Research

Ligand (LGND) first-quarter earnings and sales decrease year over year.